Status:
UNKNOWN
Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD
Lead Sponsor:
Barnes Retina Institute
Collaborating Sponsors:
QLT Inc.
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the benefits, if any, of combination therapy with Lucentis plus reduced fluence photodynamic therapy with Visudyne.
Detailed Description
The study will have two treatment groups. Each group will receive intravitreal injections (injection of medication in the jelly-like part of the back of the eye). One group (Group1) of approximately 1...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Ability to give informed consent
- Treatment- naïve patients with active, subfoveal, exudative AMD
- Patients with visual acuity of 20/40-20/320 in the study eye
- Subfoveal choroidal neovascularization (CNV) must be at least 50% of the total lesion size Total area of lesion components other that CNV must be less than 50% of the total lesion size
- The lesion must be \< 5400microns in greatest linear dimension (GLD)
- Lesion size \< 10 DA
- Occult with no classic CNV lesions must have presumed recent disease progression:
- Blood associated with the lesion at baseline
- Loss of visual acuity in the previous 3 months: a: \> 5 letter loss (ETDRS equivalent) or b: 2 or more lines using a snellen or equivalent chart
- \> 10% increase in GLD as assessed by fluorescein angiography in the previous 3 months
- Previous treatment for CNV with anti-VEGF agents, intraocular steroids and/or Photodynamic therapy with Visudyne® in the study eye
- Geographic atrophy or fibrosis in the study eye
- Intraocular surgery within 6 weeks of enrollment
- Subretinal hemorrhage \> 50% of the total lesion
- Patients with intraocular pressure greater than 30 mm/Hg on 2 pressure-lowering medications
- Patients with severe disciform scarring.
- Inability to make study visits
- Advanced glaucoma
- Allergies to porfins or a known hypersensitivity to any component of Visudyne®
- Patients with porphyria
- Pregnancy or lactation
Exclusion
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00455871
Start Date
April 1 2007
End Date
October 1 2010
Last Update
May 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barnes Retina Institute
St Louis, Missouri, United States, 63110